Compare AQST & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQST | VIR |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 825.0M |
| IPO Year | 2018 | 2019 |
| Metric | AQST | VIR |
|---|---|---|
| Price | $3.92 | $5.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $8.83 | ★ $25.73 |
| AVG Volume (30 Days) | ★ 4.3M | 1.7M |
| Earning Date | 11-05-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,397,000.00 | $16,860,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.34 | $46.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.12 | $4.16 |
| 52 Week High | $7.55 | $13.74 |
| Indicator | AQST | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 22.22 | 45.56 |
| Support Level | $5.86 | $5.55 |
| Resistance Level | $6.59 | $6.30 |
| Average True Range (ATR) | 0.32 | 0.30 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 11.98 | 39.60 |
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.